Premium
Interaction between Ketoconazole and Almotriptan in Healthy Volunteers
Author(s) -
Fleishaker Joseph C.,
Herman Beth D.,
Carel Barbara J.,
Azie Nkechi E.
Publication year - 2003
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1177/0091270003252242
Subject(s) - ketoconazole , pharmacokinetics , cyp3a4 , pharmacology , crossover study , medicine , urine , chemistry , endocrinology , metabolism , antifungal , placebo , alternative medicine , cytochrome p450 , dermatology , pathology
The interaction between almotriptan, a 5‐HT 1B/1D agonist, and the potent CYP3A4 inhibitor ketoconazole was examined in 16 healthy volunteers. Subjects received (A) 12.5 mg almotriptan orally on Day 2 of a 3‐day regimen of 400 mg ketoconazole once daily and (B) 12.5 mg almotriptan in a crossover design. Plasma and urine concentrations of almotriptan were measured by HPLC. Treatment effects on almotriptan pharmacokinetics were assessed by analysis of variance. Ketoconazole coadministration increased mean almotriptan AUC and C max from 312 to 490 ng h/mL and 52.6 to 84.5 ng/mL, respectively. Mean oral clearance was decreased from 40.7 to 26.2 L/h by ketoconazole, with an accompanying increase in the fraction of almotriptan excreted unchanged in the urine (40.6% to 53.3%) and a decrease in renal clearance (16.4 to 13.8 L/h). These effects were statistically significant. The effects of ketoconazole on almotriptan clearance were consistent with inhibition of the CYP3A4‐mediated metabolism and a slight effect on the active tubular secretion of almotriptan.